Related Experiment Video
Updated: Jun 19, 2026
07:49
Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
Common mitochondrial polymorphisms as risk factor for endometrial cancer
Anna M Czarnecka1,2, Aleksandra Klemba1, Andrzej Semczuk3
1Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Pawinskiego 5a, 02-106, Warsaw, Poland.
International Archives of Medicine
|October 30, 2009
Summary
Mitochondrial DNA (mtDNA) analysis in endometrial cancer revealed specific genetic variations. Certain mtDNA polymorphisms and haplogroup distributions may influence cancer development and offer potential diagnostic markers.
Area of Science:
- Gynecologic Oncology
- Cancer Genetics
- Mitochondrial Genomics
Background:
- Endometrial carcinoma is a prevalent gynecological cancer with a lack of established diagnostic and prognostic markers.
- Mitochondrial DNA (mtDNA) mutations are increasingly recognized as potential contributors to various cancers.
- The role of inherited mitochondrial genetic background in endometrial adenocarcinoma susceptibility requires further investigation.
Purpose of the Study:
- To investigate the presence and distribution of somatic mtDNA mutations and inherited polymorphisms in endometrial adenocarcinoma.
- To analyze mitochondrial haplogroup frequencies in patients with endometrial carcinoma compared to the general population.
- To explore the potential of mtDNA analysis as a molecular tool for cancer detection.
Main Methods:
- Analysis of the D-loop sequence in cancer and normal tissue samples from endometrial adenocarcinoma patients.
- Detection of somatic mutations and inherited polymorphisms within the mitochondrial DNA.
- Mitochondrial haplogroup analysis and statistical comparison with population data.
Main Results:
- Two somatic mutations were identified in the D-loop region of mtDNA.
- An increased incidence of specific mtDNA polymorphisms (16223C, 16126C, 207A) was observed in patients.
- Haplogroup distribution in endometrial carcinoma patients differed significantly from the Polish population, with haplogroup H being underrepresented.
Conclusions:
- mtDNA polymorphisms appear to contribute to the genetic background of endometrial adenocarcinoma development.
- The underrepresentation of haplogroup H suggests a potential cancer-protective role.
- mtDNA analysis holds promise for the development of novel molecular diagnostic tools for endometrial cancer.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:59Animal Mitochondrial Genetics
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:20Mismatch Repair
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...